Guangzhou Wondfo Biotech Co.,Ltd (300482.SZ) Bundle
From its founding by Wen Mei Li on May 18, 1992 to becoming the first Chinese POCT company listed on the Shenzhen Stock Exchange in 2015 (ticker 300482.SZ), Guangzhou Wondfo Biotech has built a vertically integrated IVD and POCT powerhouse that now distributes products to more than 140 countries through over 20 global subsidiaries, leverages R&D centers in San Diego and Guangzhou and nine technology platforms spanning colloidal gold to molecular diagnostics, and-with a market capitalization of about USD 1.7 billion reported in 2017-generates revenue by selling a diverse portfolio of rapid test kits, customized distributor services and instrument solutions while operating factories across Asia, South America, Africa and the CIS to shorten delivery times and control costs.
Guangzhou Wondfo Biotech Co.,Ltd (300482.SZ): Intro
Guangzhou Wondfo Biotech Co.,Ltd (300482.SZ) is a Chinese in vitro diagnostics (IVD) and point-of-care testing (POCT) company founded on May 18, 1992, by Wen Mei Li. Since inception it has focused on rapid diagnostics, immunoassays, molecular POCT, and vertically integrated manufacturing and distribution to serve clinical, public health and consumer markets.- Founded: May 18, 1992 (Founder: Wen Mei Li)
- Stock listing: Shenzhen Stock Exchange, 2015 (first Chinese POCT company listed)
- Global reach: Products distributed to more than 140 countries and regions
- Operational footprint: >20 subsidiaries worldwide
- R&D centers: San Diego (USA) and Guangzhou (China)
- Manufacturing footprint: invested factories across Asia, South America, Africa and the Commonwealth of Independent States (CIS)
| Attribute | Detail / Number |
|---|---|
| Established | May 18, 1992 |
| Founder | Wen Mei Li |
| Stock code | 300482.SZ (Shenzhen Stock Exchange) |
| Listing milestone | 2015 - first Chinese POCT company listed on SZSE |
| Global distribution | Products in >140 countries and regions |
| Subsidiaries | More than 20 worldwide |
| R&D centers | San Diego (USA), Guangzhou (China) |
| Manufacturing network | Factories across Asia, South America, Africa, CIS |
History & major milestones
- 1992 - Company founded in Guangzhou with an initial focus on rapid test strips and IVD reagents.
- 2000s - Expanded product portfolio into immunoassay and molecular POCT platforms; scaled manufacturing.
- 2015 - Listed on Shenzhen Stock Exchange (300482.SZ), becoming the first listed Chinese POCT company.
- 2010s-2020s - Built global manufacturing and distribution footprint; established R&D center in San Diego to accelerate assay and platform innovation.
- By 2024 - Achieved market presence in over 140 countries and established more than 20 subsidiaries to support local distribution, technical service, and regulatory filings.
Ownership & corporate structure
- Listed parent: Guangzhou Wondfo Biotech Co.,Ltd (300482.SZ) - publicly traded entity on SZSE.
- Corporate subsidiaries: Operating subsidiaries across key regions (Asia, South America, Africa, CIS, North America) to localize manufacturing, shorten delivery lead times, and reduce logistics costs.
- R&D units: Dual-center model (Guangzhou and San Diego) to integrate domestic capabilities with international research collaborations.
Mission, vision & values (reference)
Mission Statement, Vision, & Core Values (2026) of Guangzhou Wondfo Biotech Co.,Ltd.How it works - core business model
- Product development: Internal R&D designs reagents, lateral flow assays, immunoassay kits and molecular POCT platforms; San Diego and Guangzhou centers focus on platform innovation and assay validation.
- Manufacturing: Multi-region factories produce test kits and instruments to lower freight/time-to-customer and meet local regulatory/market needs.
- Regulatory & quality: Centralized quality systems and regional registration teams secure CE, WHO/Prequalification where applicable, and country-specific approvals.
- Sales & distribution: Direct sales, distributors, and >20 subsidiaries deliver products, OEM services, and technical support across >140 countries.
- After-sales & service: Local technical teams provide training, warranty service, and consumable supply to drive recurring revenue.
How it makes money - revenue streams
- Consumables and reagents: Recurring sales of single-use test kits and reagents for POCT and IVD instruments (core revenue driver).
- Instruments and platforms: Sale of POCT analyzers, readers and integrated testing systems (one-time and upgrade revenue plus installed base).
- OEM/ODM contracts: Custom development and contract manufacturing for domestic and international partners.
- Service & support: Training, maintenance contracts, and localized technical services that support instrument uptime and consumables consumption.
- Export sales: Global distribution to clinical labs, hospitals, public health programs and NGOs across >140 countries; localized manufacturing reduces cost and delivery time to these markets.
Guangzhou Wondfo Biotech Co.,Ltd (300482.SZ): History
Guangzhou Wondfo Biotech Co.,Ltd (300482.SZ) was founded by Wen Mei Li and grew from a diagnostics start-up into one of China's leading in vitro diagnostics and rapid-test manufacturers. The company leveraged early innovation in lateral flow assays and immunoassays to expand into global markets, public-health screening, and consumer diagnostics.- Founded by Wen Mei Li - entrepreneurial leadership central to R&D and international expansion.
- Listed on the Shenzhen Stock Exchange (ticker 300482.SZ) - provided capital for scale-up and new product lines.
- Product focus: infectious disease rapid tests, pregnancy/ovulation tests, POCT devices, and reagent kits.
- Global reach with manufacturing and distribution across Asia, Latin America, Europe, and Africa.
- Publicly traded entity with shares held by a mix of institutional investors, mutual funds, other corporate investors, and retail holders.
- Founder and founding group retain meaningful influence through direct and indirect shareholdings and board representation.
- Listing on Shenzhen enabled access to equity capital, supporting acquisitions, capacity expansion, and R&D investments.
- Stock liquidity: actively traded on the Shenzhen exchange, reflecting investor interest in the Chinese biotech/diagnostics sector.
| Metric | Value (approx.) | Notes / Period |
|---|---|---|
| Ticker | 300482.SZ | Shenzhen Stock Exchange |
| Founder | Wen Mei Li | Founder and major promoter |
| Revenue (annual) | ≈ RMB 7.2 billion | Fiscal year ~2023 (approximate) |
| Net profit (annual) | ≈ RMB 0.9 billion | Fiscal year ~2023 (approximate) |
| Market capitalization | ≈ RMB 30 billion | Mid‑2024 indicative market value |
| Shares outstanding | ≈ 1.2 billion | Basic shares outstanding (approx.) |
| Major shareholders | Founder group, institutional investors, retail | Diverse shareholder base influencing governance |
- Access to public markets has enabled capital raises for factory expansion, automation, and clinical validation studies.
- Institutional investors provide governance oversight, pushing for profitability, compliance, and internationalization.
- Founder-led governance maintains strategic continuity in product development and partnerships.
Guangzhou Wondfo Biotech Co.,Ltd (300482.SZ): Ownership Structure
Guangzhou Wondfo Biotech Co.,Ltd (300482.SZ) is a leading Chinese point-of-care testing (POCT) and in vitro diagnostics (IVD) company focused on rapid diagnostics, chronic disease management, and related lab equipment. Its stated mission emphasizes safeguarding health and improving lives globally by delivering innovative, reliable diagnostic solutions and building trusted partnerships across healthcare systems. See the company's formal positioning here: Mission Statement, Vision, & Core Values (2026) of Guangzhou Wondfo Biotech Co.,Ltd. Mission and values- Focus: develop rapid diagnostics and chronic disease-management tools for hospitals, clinics, and community settings.
- Innovation: sustained investment in R&D to retain competitive edge in POCT and expand product pipelines (immunoassays, molecular tests, biosensors).
- Quality & reliability: manufacturing and regulatory compliance aimed at consistent product performance and customer trust.
- Stakeholder orientation: align with expectations of employees, customers, partners, and regulators-philosophy captured by "Earn everyone's trust by serving them the best."
- Product lines: rapid test strips/cards, lateral-flow immunoassays, molecular POCT platforms, clinical chemistry reagents, and point-of-care instruments.
- Sales channels: direct sales to hospitals and CDCs, distributors, international exports (EMEA, LATAM, APAC), and OEM partnerships.
- Revenue streams: product sales (diagnostics kits and instruments), after-sales service & consumables, and licensing/OEM agreements.
- Competitive model: recurring consumables revenue from test kits + installed base growth of instruments and service contracts.
| Item | Value |
|---|---|
| Listed code | 300482.SZ |
| Approx. FY2023 revenue | RMB 6.5 billion |
| Approx. FY2023 net profit (attributable) | RMB 1.1 billion |
| R&D spend (FY2023) | RMB 320 million (~4.9% of revenue) |
| Gross margin (FY2023) | ~52% |
| Export share of revenue | ~22% |
- Major shareholder group (founder/holding entities): ~25% - strategic control and board influence.
- Institutional investors and funds: ~15% - includes domestic and selective offshore institutional holders.
- Company employees and management (including ESOPs): ~7%.
- Public/free float (retail and other institutional holders): ~53%.
Guangzhou Wondfo Biotech Co.,Ltd (300482.SZ): Mission and Values
Guangzhou Wondfo Biotech Co.,Ltd (300482.SZ) is built on a mission to expand access to timely, accurate in vitro diagnostics (IVD) and point-of-care testing (POCT) through integrated innovation, localized manufacturing, and global distribution. Its core values emphasize scientific rigor, patient-centricity, rapid delivery, and partnerships that scale diagnostics into routine care. How It Works Wondfo operates a vertically integrated model spanning research & development, manufacturing, sales, and after-sales service for IVD and POCT products. This end-to-end integration enables rapid product iteration, consistent quality control, cost efficiencies, and faster market deployment.- Research & Development: Multi-site R&D with centralized strategy to convert discoveries into commercial assays and instruments.
- Manufacturing: Owned factories across multiple continents to shorten lead times and lower logistics costs.
- Sales & Service: Direct sales, distributors, and local technical support through subsidiaries to serve clinics, hospitals, labs and public health systems.
| Technology Platform | Main Uses / Typical Tests |
|---|---|
| Immune Colloidal Gold | Rapid antigen/antibody tests for infectious disease, pregnancy, drug abuse screening |
| Immuno-fluorescence | High-sensitivity antibody/antigen detection for infectious and autoimmune markers |
| Electrochemistry | POCT biochemical markers, cardiac markers (e.g., troponin), metabolic panels |
| Dry Biochemistry | Glucose, lipids, renal function panels for decentralized testing |
| Chemiluminescence | High-throughput immunoassays for hormones, tumor markers, infectious serology |
| Molecular Diagnostics | PCR/NAAT assays for respiratory, sexually transmitted and other infectious pathogens |
| Instrument | Readers, analyzers and integrated POCT platforms for point-of-care deployment |
| Pathology | Immunohistochemistry reagents and instruments for tumor diagnostics |
| Biological Raw Material | Antibodies, antigens, recombinant proteins used across assay development |
- Cardiovascular disease markers (e.g., troponin, BNP)
- Diabetes monitoring (glucose, HbA1c adjunct systems)
- Renal function (creatinine, BUN panels)
- Respiratory pathogens (influenza, SARS-CoV-2, RSV)
- Fertility and reproductive hormones
- Drug of abuse screening
- Infectious disease serology and antigen tests
- Oncology biomarkers and pathology reagents
- R&D centers: Guangzhou (China) and San Diego (USA), combining local clinical insight with US-based translational research capabilities.
- Manufacturing network: Owned and invested factories across Asia, South America, Africa and the CIS to reduce delivery time and logistics costs.
- Subsidiaries & reach: More than 20 subsidiaries worldwide supporting customers in over 140 regions and countries.
| Metric | Value | Fiscal Year / Note |
|---|---|---|
| Revenue | ≈ RMB 6.5 billion | FY 2023 (approx.) |
| Net Profit (attributable) | ≈ RMB 700 million | FY 2023 (approx.) |
| R&D Investment | ~8-10% of revenue | Company target range / annual trend |
| Employees | ~8,000 | Global headcount (approx.) |
| Subsidiaries | >20 | Worldwide |
| Market Reach | >140 countries/regions | Distribution footprint |
- Product sales: Kits and consumables (major recurring revenue source across IVD/POCT assays).
- Instruments: Readers and analyzers sold as capital equipment, often driving recurring reagent sales.
- OEM/ODM manufacturing: Contract manufacturing and private-label supply for partners and public health procurements.
- Solutions & services: Diagnostic solutions for hospitals, screening programs and public health initiatives, including technical support and training.
- Geographic diversification: Local factories and subsidiaries reduce shipping cost and tariff exposure, enabling competitive pricing in emerging markets.
- Vertical integration reduces intermediary margins and improves gross margin stability.
- Proprietary platforms (nine technology bases) enable product portfolio breadth and cross-selling.
- Global manufacturing footprint lowers lead times and logistics cost, improving win rates in tenders and emergency procurements.
- R&D centers in China and the US facilitate faster regulatory strategy alignment and market entry across regions.
Guangzhou Wondfo Biotech Co.,Ltd (300482.SZ): How It Works
Guangzhou Wondfo Biotech Co.,Ltd (300482.SZ) is a leading developer, manufacturer and distributor of in vitro diagnostics (IVD) and point-of-care testing (POCT) products. The company combines product manufacturing, customized distribution services and global infrastructure to monetize diagnostic technologies across public health, clinical and consumer channels.- Product portfolio: lateral flow rapid test kits (infectious diseases, pregnancy, drugs of abuse, cardiac markers), immunoassay analyzers, molecular POCT systems and reagents.
- Channels: direct sales to hospitals and clinics, professional distributors, government tenders, e‑commerce and OEM/ODM partnerships.
- Global footprint: products distributed to over 140 countries and regions, with regional subsidiaries and service centers to support logistics and after-sales.
- Direct product sales - core revenue from standardized rapid test kits and analyzers sold to clinical labs, hospitals and retail channels.
- Customized solutions and OEM/ODM - tailored assay development and contract manufacturing sold to professional distributors and partnering affiliates.
- Geographic scale - export sales across 140+ countries, with large accounts and channel partners in APAC, LATAM, Africa and EMEA boosting volumes.
- New product introductions - R&D-driven launches (molecular POCT, immunoassays) that command higher ASPs and margin expansion over commoditized lateral flow tests.
- Service & after-sales - calibration, maintenance contracts, training and reagent consumable sales that create recurring revenue.
| Metric | Value / Notes |
|---|---|
| Approx. annual revenue (recent) | RMB 6.2 billion (latest fiscal period; illustrative company-level figure) |
| Approx. net profit (recent) | RMB 0.9 billion |
| R&D spend | ~5-7% of revenue (~RMB 340 million if 5.5%) |
| Gross margin (typical) | ~35-45% depending on product mix (higher for analyzers and reagents) |
| Export footprint | Products sold in 140+ countries and regions |
| Quality systems | ISO 9001, ISO 13485, multiple CE marks and other country-specific registrations |
| Manufacturing & service centers | Domestic HQ manufacturing plus strategic global sites to shorten lead times and reduce logistics costs |
- Product mix: Rapid test kits (volume driver, lower ASP) vs. instruments & reagents (higher margin, recurring revenue).
- Customization/OEM: Contract development and private‑label supply increase capacity utilization and smooth cyclical demand.
- Geographic diversification: Export-led growth cushions domestic cycles and increases total addressable market; regulatory approvals (CE, WHO prequalification for select items) enable institutional tenders.
- R&D pipeline: Investment in molecular POCT and immunoassays designed to shift revenue composition towards higher-margin platforms over time.
- End-to-end value chain: in-house R&D → scaled manufacturing → global logistics → regional service centers → distributor partnerships.
- Quality & compliance: ISO 9001 / ISO 13485 and multiple regulatory approvals accelerate adoption by hospitals, NGOs and ministries of health, improving access to larger tenders.
- Channel strategy: mix of direct accounts for institutional buyers and an extensive distributor network for retail/remote markets, enabling both high-volume tenders and long‑tail retail sales.
- New product approvals and launches (molecular POCT, expanded immunoassay panels).
- R&D spend as % of revenue and successful commercialization rate for new platforms.
- Export growth in emerging markets and success in large institutional tenders.
- Gross margin trends as product mix shifts toward instruments/reagents.
Guangzhou Wondfo Biotech Co.,Ltd (300482.SZ): How It Makes Money
Guangzhou Wondfo Biotech (300482.SZ) generates revenue primarily by developing, manufacturing and commercializing point-of-care testing (POCT) products, in vitro diagnostics (IVD) kits and related diagnostic platforms for clinical, public health and consumer use. The company's commercial success is driven by product sales, OEM/ODM manufacturing contracts, and expansion into international markets.- Core revenue streams:
- Sales of rapid diagnostic test kits (infectious disease, pregnancy, fertility, drug testing)
- Sales of clinical chemistry and immunoassay instruments and consumables
- OEM/ODM manufacturing and long-term supply contracts
- After-sales service, calibration and reagent replacement
- Geographic reach: products sold in over 140 countries and regions, providing diversified market exposure
- Public listing: traded as 300482.SZ on the Shenzhen Stock Exchange
| Metric | Value / Note |
|---|---|
| Market capitalization (reported) | ≈ USD 1.7 billion (as of 2017) |
| Global footprint | Presence in 140+ countries and regions |
| Primary product categories | POCT rapid tests, immunoassays, clinical instruments, reagents |
| Revenue model | Product sales (domestic & export), OEM/ODM contracts, service & consumables |
| Strategic priorities | R&D investment, global manufacturing capacity, chronic disease diagnostics |
- Market position & future outlook:
- Leading player in the Chinese POCT industry with significant scale and brand recognition.
- International diversification (140+ countries) reduces single‑market risk and supports export-driven growth.
- Continuous innovation and expansion into chronic disease management and rapid diagnostics align with global healthcare trends, enhancing long‑term revenue potential.
- Strategic investments in R&D and global manufacturing capacity underpin competitiveness and potential margin improvement.
- Commitment to quality and customer satisfaction supports contract renewals, recurring consumables revenue, and new market entry.
Guangzhou Wondfo Biotech Co.,Ltd (300482.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.